Evidence map›Paper›PMID 40106333›Full record

ArticleJournal of chemical information and modeling2025

Integrated Virtual Screening Approach Identifies New CYP19A1 Inhibitors.

Sijie Liu, Jie Wu, Ya Chen, Clemens Alexander Wolf, Matthias Bureik, Johannes Kirchmair, Mario Andrea Marchisio, Gerhard Wolber

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Fingerprint-Based Machine Learning for SARS-CoV-2 and MERS-CoVJournal of chemical information and modeling · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sijie LiuPharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy, Freie Universität Berlin, 14195 Berlin, Germany.ORCID 0000-0001-8834-3881
Jie WuSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Ya ChenDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0001-5273-1815
Clemens Alexander WolfPharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy, Freie Universität Berlin, 14195 Berlin, Germany.ORCID 0000-0002-5682-1815
Matthias BureikSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.ORCID 0000-0002-9515-6248
Johannes KirchmairDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0003-2667-5877
Mario Andrea MarchisioSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Gerhard WolberPharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy, Freie Universität Berlin, 14195 Berlin, Germany.ORCID 0000-0002-5344-0048

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human cytochrome P450 19A1 (CYP19A1, aromatase) is a heme-containing protein catalyzing the final steps of the biosynthesis of the steroid hormone 17β-estradiol. It is a key target for the treatment of sex-hormone-related disorders due to its role in mediating the conversion of androgens to estrogens. Here, we report the development of a virtual screening workflow incorporating machine learning and structure-based modeling that has led to the discovery of new CYP19A1 inhibitors. The machine learning models were built on comprehensive CYP19A1 data sets extracted from the ChEMBL and PubChem Bioassay databases and subjected to thorough validation routines. Ten promising hits that resulted from the virtual screening campaign were selected for experimental testing in an enzymatic assay based on heterologous expression of human CYP19A1 in yeast. Among the seven structurally diverse compounds identified as new CYP19A1 inhibitors, compound

Indexed as

AromataseAromatase InhibitorsUser-Computer InterfaceDrug Evaluation, PreclinicalHumansMachine LearningMolecular Docking SimulationAromataseAromatase InhibitorsCYP19A1 protein, human

Identifiers

PMID40106333
PMCPMC12004523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.